Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Reported May 14, 2025: TransCode Therapeutics Q1 EPS $(2.51) Misses $(2.00) Estimate

Author: Benzinga Newsdesk | May 15, 2025 08:56am
TransCode Therapeutics (NASDAQ:RNAZ) reported quarterly losses of $(2.51) per share which missed the analyst consensus estimate of $(2.00) by 25.5 percent. This is a 88.24 percent increase over losses of $(21.35) per share from the same period last year.

Posted In: RNAZ


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist